# Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load

> **NCT04336943** · PHASE2 · TERMINATED · sponsor: **University of Washington** · enrollment: 6 (actual)

## Conditions studied

- Biochemically Recurrent Prostate Carcinoma
- Prostate Adenocarcinoma

## Interventions

- **BIOLOGICAL:** Durvalumab
- **DRUG:** Olaparib
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT04336943
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-13
- **Primary completion:** 2024-06-20
- **Final completion:** 2025-06-06
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2025-08-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04336943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04336943, "Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04336943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*